Fazeela Morshed

US Patent:

58243097, Oct 20, 1998

Filed:

Dec 5, 1996

Appl. No.:

8/759444

Inventors:

Shiladitya DasSarma - Amherst MA
Fazeela Morshed - Amherst MA
Elizabeth Stuart - Amherst MA
Samuel Black - Leverett MA

Assignee:

University of Massachusetts - Boston MA

International Classification:

A61K 3921
A61K 3902
A61K 39295
C07K 14195

US Classification:

4241881

Abstract:

The invention features a composition that includes a substantially pure recombinant gas vesicles which have at least one heterologous peptide inserted into at one of their structural proteins. The recombinant gas vesicle, when administered to a mammal, is capable of eliciting antibodies which specifically bind to the heterologous peptide. The heterologous peptide can be any peptide against which one wishes to raise antibodies, e. g. , a peptide found in the gp12O protein of human immunodeficiency virus (HIV).

US Patent:

20210261557, Aug 26, 2021

Filed:

Apr 27, 2021

Appl. No.:

17/242016

Inventors:

- Cambridge MA, US
Cassandra CELATKA - Hull MA, US
Seng CHENG - Natick MA, US
Mary A. CROMWELL - Groton MA, US
Andrew GOOD - Wallingford CT, US
Bradford HIRTH - Framingham MA, US
Katherine JANCSICS - Wilmington MA, US
John P. LEONARD - Manchester NH, US
Lingyun LI - Waltham MA, US
James LILLIE - Wellesley MA, US
Hanlan LIU - Lexington MA, US
Elina MAKINO - Winchester MA, US
John MARSHALL - Hopedale MA, US
Paul MASON - Natick MA, US
Markus METZ - Waltham MA, US
Fazeela MORSHED - Waltham MA, US
Thomas O'SHEA - Wellesley MA, US
Ronald SCHEULE - Hopkinton MA, US
Renato SKERLJ - West Newton MA, US
Bing WANG - Newton MA, US
Yibin XIANG - Dracut MA, US
Zhong ZHAO - Wayland MA, US

Assignee:

GENZYME CORPORATION - Cambridge MA

International Classification:

C07D 487/08
A61K 31/439
A61K 31/454
A61K 38/47
C07D 453/02
C07D 453/00
A61K 31/46
A61K 31/506
A61K 31/551
C07D 455/02

Abstract:

The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.

US Patent:

20200048266, Feb 13, 2020

Filed:

Aug 15, 2019

Appl. No.:

16/542166

Inventors:

- Cambridge MA, US
Cassandra CELATKA - Hull MA, US
Seng CHENG - Natick MA, US
Mary A. CROMWELL - Groton MA, US
Andrew GOOD - Wallingford CT, US
Bradford HIRTH - Framingham MA, US
Katherine JANCSICS - Wilmington MA, US
John P. LEONARD - Manchester NH, US
Lingyun LI - Waltham MA, US
James LILLIE - Wellesley MA, US
Hanlan LIU - Lexington MA, US
Elina MAKINO - Winchester MA, US
John MARSHALL - Hopedale MA, US
Paul MASON - Natick MA, US
Markus METZ - Waltham MA, US
Fazeela MORSHED - Waltham MA, US
Thomas O'SHEA - Wellesley MA, US
Ronald SCHEULE - Hopkinton MA, US
Renato SKERLJ - West Newton MA, US
Bing WANG - Newton MA, US
Yibin XIANG - Dracut MA, US
Zhong ZHAO - Wayland MA, US

International Classification:

C07D 487/08
A61K 31/439
A61K 31/454
A61K 38/47
C07D 453/02
C07D 453/00
A61K 31/46
A61K 31/506
A61K 31/551
C07D 455/02

Abstract:

The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.

US Patent:

20160207933, Jul 21, 2016

Filed:

Aug 25, 2015

Appl. No.:

14/835402

Inventors:

- Cambridge MA, US
Cassandra CELATKA - Hull MA, US
Seng CHENG - Natick MA, US
Mary A. CROMWELL - Groton MA, US
Andrew GOOD - Wallingford CT, US
Bradford HIRTH - Framingham MA, US
Katherine JANCSICS - Wilmington MA, US
John P. LEONARD - Manchester NH, US
Lingyun LI - Waltham MA, US
James LILLIE - Wellesley MA, US
Hanlan LIU - Lexington MA, US
Elina MAKINO - Winchester MA, US
John MARSHALL - Hopedale MA, US
Paul MASON - Natick MA, US
Markus METZ - Waltham MA, US
Fazeela MORSHED - Waltham MA, US
Thomas O'SHEA - Wellesley MA, US
Ronald SCHEULE - Hopkinton MA, US
Renato SKERLJ - West Newton MA, US
Bing WANG - Newton MA, US
Yibin XIANG - Dracut MA, US
Zhong ZHAO - Wayland MA, US

International Classification:

C07D 487/08
A61K 31/439
A61K 38/47
A61K 31/551
C07D 455/02
A61K 31/46
C07D 453/02
A61K 31/506

Abstract:

The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.